March 11, 2026. 16 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.
This regulatory action schedules synthetic amphetamines (DOI and DOC) as controlled substances, with minimal direct relevance to cannabis medicine practice or patient treatment protocols.
The DEA temporarily classified six synthetic cannabinoids into Schedule I, restricting their legal availability and potentially affecting cannabis clinicians’ understanding of illicit cannabinoid analogs and patient safety concerns.
Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I
Regulatory Summary
This DEA action schedules ethylphenidate (a synthetic stimulant) as a controlled substance, establishing regulatory precedent for novel psychoactive compounds but having limited direct clinical relevance to cannabis prescribing or patient care.
Schedules of Controlled Substances: Placement of Metonitazene in Schedule I
Regulatory Summary
The DEA placed metonitazene, a synthetic opioid, into Schedule I, establishing it as a controlled substance with no medical use—relevant to cannabis clinicians managing pain patients who may seek cannabis as an alternative to scheduled opioids.
Regulatory Summary
This DEA action scheduled synthetic benzodiazepines as controlled substances, relevant to cannabis clinicians managing patients using these drugs concurrently or as alternative anxiolytics.
Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224
Regulatory Summary
A biopharmaceutical company applied to become a DEA-licensed controlled substance importer, potentially enabling legal cannabis research and therapeutic development for clinical use.
Importer of Controlled-Bright Green(2024-20083)DEA1426
Regulatory Summary
DEA approval for controlled substance importation under registration 2024-20083 establishes legal framework for acquiring regulated cannabis materials for clinical research, treatment protocols, or pharmaceutical development purposes.
Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429
Regulatory Summary
DEA permit 2024-20082 authorizes Cambridge Isotope as a controlled substance importer, enabling production of labeled cannabis research materials for clinical studies and therapeutic development.
CMS updates 2025 Medicare Part B payment policies and coverage determinations, potentially affecting reimbursement rates and covered services that cannabis clinicians bill to Medicare or Medicaid for patient care.
This CMS proposed rule updates Medicare/Medicaid payment policies and coverage requirements, potentially affecting reimbursement for healthcare services cannabis clinicians provide to Medicare beneficiaries in 2025.
Bulk Manufacturer-Royal Emerald (2024-11786) DEA1368
Regulatory Summary
DEA approval of Royal Emerald as a bulk cannabis manufacturer enables increased therapeutic supply availability for clinical research and patient access through licensed medical cannabis programs.
Importer Controlled-VA Cooperative (2024-11795) DEA1374
Regulatory Summary
The DEA importer controlled substance cooperative (2024-11795) establishes controlled substance importation procedures relevant to cannabis clinicians and patients seeking regulated access to cannabis-derived medicines.
Importer Controlled- Quagen Pharma (2024-11892) DEA1381
Regulatory Summary
DEA Form 1381 filed for Quagen Pharma’s importer controlled status in 2024, potentially affecting cannabis-derived pharmaceutical product importation and availability for clinical use.
Exempt Chemical Preparations May 2024 (2024-10465) – DEA372
Regulatory Summary
The DEA’s May 2024 exemption guidance clarifies which chemical preparations containing controlled substances may be exempt from certain regulatory requirements, potentially affecting cannabis product formulations and clinical applications.
This CMS final rule establishes 2024 Medicare/Medicaid payment policies and coverage requirements, potentially affecting reimbursement eligibility and clinical documentation standards for cannabis-based treatments within federally-funded healthcare programs.
CMS 2024 payment policies may affect cannabis medicine reimbursement and coverage determinations under Medicare and Medicaid, impacting clinician billing practices and patient access to cannabis-based treatments.
Digest-Level Clinical Commentary
Clinical Reflection
These items reveal a fragmented regulatory landscape where cannabis medicine practitioners operate: while items 1-5 demonstrate the DEA’s continued aggressive scheduling of novel synthetic cannabinoids and designer drugs that create clinical confusion and public health risks, items 6-14 show simultaneous federal movement toward legitimizing pharmaceutical supply chains for controlled substances, suggesting the infrastructure exists for cannabis rescheduling but remains politically withheld. Items 9-10 and 15 indicate Medicare/Medicaid are actively modernizing payment structures for controlled substances without cannabis inclusion, which functionally excludes evidence-based cannabis interventions from reimbursement despite growing clinical trial data supporting efficacy for chronic pain, chemotherapy-induced nausea, and treatment-resistant epilepsy. This disconnect between regulatory capacity and political will creates a two-tiered system where synthetic
Clinical Perspective
These regulatory items reflect two concurrent policy priorities: ongoing efforts to control emerging synthetic drugs and analogs through DEA scheduling, and broader healthcare administration reforms focused on medication access and payment structures under Medicare and Medicaid. The scheduling actions address the persistent challenge of novel psychoactive substances that evade existing regulations, while the payment policy updates indicate continued emphasis on cost management and accountability in pharmaceutical distribution. Together, these represent the routine but essential regulatory work required to balance drug safety oversight with practical implementation of healthcare coverage policies.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: